Clinical Chemistry Analyzers Market worth $16.5 billion | F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US)

Clinical Chemistry Analyzers Market in terms of revenue was estimated to be worth $13.0 billion in 2023 and is poised to reach $16.5 billion by 2028, growing at a CAGR of 4.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. The clinical chemistry analyzers market is witnessing growth due to several factors, including the rise in the elderly population and the higher occurrence of chronic and lifestyle diseases. The increasing adoption of point-of-care testing devices and the growing demand for laboratory automation are also contributing to this growth. Additionally, emerging economies like China and Japan are offering profitable prospects for companies involved in the clinical chemistry analyzers market.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144027310&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Reagents segment accounted for the largest share of the clinical chemistry analyzers market, by product segment, in 2022

The clinical chemistry analyzers market is categorized into reagents, analyzers, and other products based on the product type. In 2022, the reagents segment held the largest market share in the clinical chemistry analyzers market. The primary driver for the growth of this segment is the consistent and high demand for reagents, which surpasses the demand for analyzers.

Lipid profile tests segment to register the highest growth rate during the forecast period

Segmented by test type, the clinical chemistry analyzers market includes basic metabolic panels, electrolyte panels, liver panels, lipid profiles, renal profiles, thyroid function panels, and specialty chemical tests. In 2022, the lipid profile tests segment exhibited the highest growth rate in the market. This growth can be attributed to the rapid increase in obesity rates and the rising prevalence of diseases associated with obesity.

The hospitals and clinics segment accounted for the largest share of the clinical chemistry analyzers market, by end user segment, in 2022

The clinical chemistry analyzers market is divided into hospitals and clinics, diagnostic laboratories, research laboratories and institutes, and other end users based on end-users. In 2022, hospitals and clinics held the largest market share in the clinical chemistry analyzers market. The growth of this segment is primarily driven by factors such as the rising global incidence of diseases and disorders, the growing adoption of analyzers in healthcare settings, and continuous technological advancements.

North America is the largest regional market for clinical chemistry analyzers market

The clinical chemistry analyzers market is categorized into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America held the largest market share in the clinical chemistry analyzers market. The dominant position of this region can be attributed to various factors, including the growing geriatric population, rising incidence of chronic and lifestyle diseases, favorable government initiatives, increased healthcare expenditure, improved healthcare infrastructure, and the presence of technologically advanced instruments.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=144027310&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Clinical Chemistry Analyzers Market Dynamics:

Drivers:

Expanding geriatric population and the increasing prevalence of chronic & lifestyle diseases
Restraints:

The requirement of high capital investments and a shortage of skilled laboratory technicians
Opportunities:

Clinical chemistry analyzers are constantly evolving
Challenges:

Increasing Regulatory Requirements

Key Market Players:

The major players operating in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), Siemens AG (Germany), HORIBA Ltd. (Japan), Sysmex Corporation (Japan), HITACHI (Japan), EKF Diagnostics (UK), Ortho Clinical Diagnostics (US), ELITech Group (France), Mindray Medical International Ltd. (China), BIOBASE Group (China), SFRI Medical Diagnostics (France), Trivitron Healthcare Pvt. Ltd. (India), Randox Laboratories Ltd. (UK), Medica Corporation (US), Meril Life Sciences Pvt. Ltd. (India), Erba Mannheim (UK), Genrui Biotech Inc. (China), DIRUI Industrial Co. Ltd. (China), Teco Diagnostics (US), Balio Diagnostics (France), Snibe Co. Ltd. (China), and AMS Alliance (Italy).

Recent Developments:

In May 2023, Siemens Healthineers AG(Germany) launched two new solutions for high-volume hematology testing, the Atellica HEMA 570 and 580 Analyzer.

In May 2022, Mindray Medical International Ltd. (China) launched the BS-600M, a powerful, efficient chemistry analyzer that is designed to empower medium-volume laboratories with increased productivity, efficiency, and reliability.

In February 2021, Thermo Fisher Scientific Inc. (US) partnered with Mindray Medical International ltd. (China) to provide customers in the United States and Canada with two clinical chemistry analyzers for drug screening in clinical and forensic laboratories.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=144027310&utm_source=OPenpr&utm_campaign=Paid&utm_content=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.